Elinzanetant for Vasomotor Symptoms in Endocrine Therapy for Breast Cancer: A Phase 3 Evidence Synthesis

Elinzanetant, a neurokinin 1 and 3 receptor antagonist, significantly reduces moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer or prevention.
The phase 3 OASIS-4 trial demonstrated robust efficacy at both week 4 and week 12, with sustained symptom reduction over 52 weeks.
Adverse events were mostly mild to moderate; common events included headache, fatigue, and somnolence, with a low incidence of serious adverse events.
This study fills a critical gap in managing vasomotor symptoms within a sensitive oncology population where hormonal and typical menopausal symptom treatments are limited due to cancer recurrence risks.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Elinzanetant, a neurokinin 1 and 3 receptor antagonist, significantly reduces moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer or prevention.
The phase 3 OASIS-4 trial demonstrated robust efficacy at both week 4 and week 12, with sustained symptom reduction over 52 weeks.
Adverse events were mostly mild to moderate; common events included headache, fatigue, and somnolence, with a low incidence of serious adverse events.
This study fills a critical gap in managing vasomotor symptoms within a sensitive oncology population where hormonal and typical menopausal symptom treatments are limited due to cancer recurrence risks.

Sign in free to continue reading